Professional Marketing briefs: August 2013

Share this article:
OPDP not happy with Diclegis promo
OPDP not happy with Diclegis promo

Medicaid has signed on to cover Duchesnay USA's morning-sickness med ­Diclegis, which launched in May. It is the only FDA-approved pregnancy sickness drug, and the first one on the market in three decades. While the company couldn't share any specifics about how it will be touting the new coverage, it says that OB/GYNs, midwives and Nurse Practitioners will be seeing the news.

While Eli Lilly's recent foray does promote the company itself, it diverges from most marketing in a very specific way—it is brand-free. The drug maker is sponsoring the MDLinx oncology app for a year, and tells MM&M “there will not be any promotion of any Lilly product.” Lilly says it's part of going “above and beyond” giving customers and physicians “access to the right [kind] of information they need.”

The FDA's bad-ad cops hit Sigma Tau with a May 22 untitled letter that said the company's sales aid for its cancer med Oncaspar was misleading. The regulator picked up the materials at the 52nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, and said that violations included unsubstantiated superiority clams and omission of material facts, among other others.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?